Brad Poore1, Ming Yuan1, Antje Arnold1, Antoinette Price1, Jesse Alt2, Jeffrey A Rubens3,4, Barbara S Slusher2,5, Charles G Eberhart1,3, Eric H Raabe1,3,4. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Division of Pediatric Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 5. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
BACKGROUND: Pediatric low-grade glioma (pLGG) often initially responds to front-line therapies such as carboplatin, but more than 50% of treated tumors eventually progress and require additional therapy. With the discovery that pLGG often contains mammalian target of rapamycin (mTOR) activation, new treatment modalities and combinations are now possible for patients. The purpose of this study was to determine if carboplatin is synergistic with the mTOR complex 1 inhibitor everolimus in pLGG. METHODS: We treated 4 pLGG cell lines and 1 patient-derived xenograft line representing various pLGG genotypes, including neurofibromatosis type 1 loss, proto-oncogene B-Raf (BRAF)-KIAA1549 fusion, and BRAFV600E mutation, with carboplatin and/or everolimus and performed assays for growth, cell proliferation, and cell death. Immunohistochemistry as well as in vivo and in vitro metabolomics studies were also performed. RESULTS: Carboplatin synergized with everolimus in all of our 4 pLGG cell lines (combination index <1 at Fa 0.5). Combination therapy was superior at inhibiting tumor growth in vivo. Combination treatment increased levels of apoptosis as well as gamma-H2AX phosphorylation compared with either agent alone. Everolimus treatment suppressed the conversion of glutamine and glutamate into glutathione both in vitro and in vivo. Exogenous glutathione reversed the effects of carboplatin and everolimus. CONCLUSIONS: The combination of carboplatin and everolimus was effective at inducing cell death and slowing tumor growth in pLGG models. Everolimus decreased the amount of available glutathione inside the cell, preventing the detoxification of carboplatin and inducing increased DNA damage and apoptosis.
BACKGROUND: Pediatric low-grade glioma (pLGG) often initially responds to front-line therapies such as carboplatin, but more than 50% of treated tumors eventually progress and require additional therapy. With the discovery that pLGG often contains mammalian target of rapamycin (mTOR) activation, new treatment modalities and combinations are now possible for patients. The purpose of this study was to determine if carboplatin is synergistic with the mTOR complex 1 inhibitor everolimus in pLGG. METHODS: We treated 4 pLGG cell lines and 1 patient-derived xenograft line representing various pLGG genotypes, including neurofibromatosis type 1 loss, proto-oncogene B-Raf (BRAF)-KIAA1549 fusion, and BRAFV600E mutation, with carboplatin and/or everolimus and performed assays for growth, cell proliferation, and cell death. Immunohistochemistry as well as in vivo and in vitro metabolomics studies were also performed. RESULTS:Carboplatin synergized with everolimus in all of our 4 pLGG cell lines (combination index <1 at Fa 0.5). Combination therapy was superior at inhibiting tumor growth in vivo. Combination treatment increased levels of apoptosis as well as gamma-H2AX phosphorylation compared with either agent alone. Everolimus treatment suppressed the conversion of glutamine and glutamate into glutathione both in vitro and in vivo. Exogenous glutathione reversed the effects of carboplatin and everolimus. CONCLUSIONS: The combination of carboplatin and everolimus was effective at inducing cell death and slowing tumor growth in pLGG models. Everolimus decreased the amount of available glutathione inside the cell, preventing the detoxification of carboplatin and inducing increased DNA damage and apoptosis.
Authors: Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack Journal: J Clin Oncol Date: 2012-06-04 Impact factor: 44.544
Authors: Allison R Hanaford; Tenley C Archer; Antoinette Price; Ulf D Kahlert; Jarek Maciaczyk; Guido Nikkhah; Jong Wook Kim; Tobias Ehrenberger; Paul A Clemons; Vlado Dančík; Brinton Seashore-Ludlow; Vasanthi Viswanathan; Michelle L Stewart; Matthew G Rees; Alykhan Shamji; Stuart Schreiber; Ernest Fraenkel; Scott L Pomeroy; Jill P Mesirov; Pablo Tamayo; Charles G Eberhart; Eric H Raabe Journal: Clin Cancer Res Date: 2016-03-24 Impact factor: 12.531
Authors: E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Geoffrey Neale; Stephen T Keir; Hernan Carol; Richard Lock; Doris Phelps; Min H Kang; C Patrick Reynolds; John M Maris; Catherine Billups; Malcolm A Smith Journal: Pediatr Blood Cancer Date: 2010-10 Impact factor: 3.167
Authors: Ralph J Hauke; Jeffrey R Infante; Mark S Rubin; Kent C Shih; Edward R Arrowsmith; John D Hainsworth Journal: Melanoma Res Date: 2013-12 Impact factor: 3.599
Authors: Hemant K Bid; Aaron Kibler; Doris A Phelps; Sagymbek Manap; Linlin Xiao; Jiayuh Lin; David Capper; Duane Oswald; Brian Geier; Mariko DeWire; Paul D Smith; Raushan T Kurmasheva; Xiaokui Mo; Soledad Fernandez; Peter J Houghton Journal: Clin Cancer Res Date: 2013-10-16 Impact factor: 12.531
Authors: Peer W F Karmaus; Andrés A Herrada; Cliff Guy; Geoffrey Neale; Yogesh Dhungana; Lingyun Long; Peter Vogel; Julian Avila; Clary B Clish; Hongbo Chi Journal: J Exp Med Date: 2017-08-07 Impact factor: 14.307
Authors: Antje Arnold; Ming Yuan; Antionette Price; Lauren Harris; Charles G Eberhart; Eric H Raabe Journal: Neuro Oncol Date: 2020-04-15 Impact factor: 12.300
Authors: Eric H Raabe; Jeffrey A Rubens; Sabrina Z Wang; Brad Poore; Jesse Alt; Antoinette Price; Sariah J Allen; Allison R Hanaford; Harpreet Kaur; Brent A Orr; Barbara S Slusher; Charles G Eberhart Journal: Clin Cancer Res Date: 2019-07-12 Impact factor: 12.531
Authors: Rebeca Piatniczka Iglesia; Mariana Brandão Prado; Rodrigo Nunes Alves; Maria Isabel Melo Escobar; Camila Felix de Lima Fernandes; Ailine Cibele Dos Santos Fortes; Maria Clara da Silva Souza; Jacqueline Marcia Boccacino; Giovanni Cangiano; Samuel Ribeiro Soares; João Pedro Alves de Araújo; Deanna Marie Tiek; Anshika Goenka; Xiao Song; Jack Ryan Keady; Bo Hu; Shi Yuan Cheng; Marilene Hohmuth Lopes Journal: Front Cell Dev Biol Date: 2022-06-15
Authors: Rachael E Maynard; Brad Poore; Allison R Hanaford; Khoa Pham; Madison James; Jesse Alt; Youngran Park; Barbara S Slusher; Pablo Tamayo; Jill Mesirov; Tenley C Archer; Scott L Pomeroy; Charles G Eberhart; Eric H Raabe Journal: Cancer Lett Date: 2021-02-08 Impact factor: 9.756
Authors: Ming Yuan; David White; Linda Resar; Eli Bar; Mari Groves; Alan Cohen; Eric Jackson; Jennifer Bynum; Jeffrey Rubens; Jeff Mumm; Liam Chen; Liqun Jiang; Eric Raabe; Fausto J Rodriguez; Charles G Eberhart Journal: Neuro Oncol Date: 2021-05-05 Impact factor: 13.029
Authors: Karen D Wright; Xiaopan Yao; Wendy B London; Pei-Chi Kao; Lia Gore; Stephen Hunger; Russ Geyer; Kenneth J Cohen; Jeffrey C Allen; Howard M Katzenstein; Amy Smith; Jessica Boklan; Kellie Nazemi; Tanya Trippett; Matthias Karajannis; Cynthia Herzog; Joseph Destefano; Jennifer Direnzo; Jay Pietrantonio; Lianne Greenspan; Danielle Cassidy; Debra Schissel; John Perentesis; Mitali Basu; Tomoyuki Mizuno; Alexander A Vinks; Sanjay P Prabhu; Susan N Chi; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2020-11-02 Impact factor: 3.838